Actinium Pharmaceuticals grants equity awards to new CFO, business development chief
ATNM•Actinium Pharmaceuticals granted stock options and restricted stock units to CFO Matt David and Senior Vice President of Business Development Sean Maenpaa, with portions tied to corporate milestones.
1. Award details
David received a 250,000-share option exercisable at $0.97 and 250,000 restricted stock units vesting over three years, plus up to 75,000 units tied to corporate milestones. Maenpaa received a 40,000-share option exercisable at $1.06 and 20,000 restricted stock units vesting annually over three years, plus 50,000 units subject to corporate milestones. Both options have ten-year terms and vest 28% after one year, then 2% monthly for 36 months; all awards require continued service.
